Literature DB >> 10370369

Bruton's tyrosine kinase controls a sustained calcium signal essential for B lineage development and function.

D J Rawlings1.   

Abstract

Genetic data support a role for Btk during the B lineage development transitions regulated by signaling through both the pre-B and the B cell antigen receptors. Dysregulated signaling at each of these transitions can result in failure of these cell populations to proliferate and subsequent cell death. Btk-dependent IP3 production is crucial for maintaining the sustained calcium signal in response to BCR engagement and is likely to regulate a subset of transcriptional events essential for B lineage growth or survival. Identification of these Btk-dependent signals will be important in understanding B cell activation, differentiation, and cell death. This information may lead to therapies specifically targeting these events in B cell autoimmunity or malignancy and provide a fuller understanding of the appropriate target populations and potential negative consequences of Btk gene therapy in XLA. Identification of Btk/Tec family kinases in an increasing number of vertebrate and invertebrate cell lineages suggests that the link between Btk and the PLC gamma/IP3/calcium signaling pathways may be broadly conserved.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10370369     DOI: 10.1006/clim.1999.4732

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  28 in total

Review 1.  Clinical consequences of defects in B-cell development.

Authors:  Andre M Vale; Harry W Schroeder
Journal:  J Allergy Clin Immunol       Date:  2010-04       Impact factor: 10.793

Review 2.  B lymphocytes: how they develop and function.

Authors:  Tucker W LeBien; Thomas F Tedder
Journal:  Blood       Date:  2008-09-01       Impact factor: 22.113

Review 3.  The genetic theory of infectious diseases: a brief history and selected illustrations.

Authors:  Jean-Laurent Casanova; Laurent Abel
Journal:  Annu Rev Genomics Hum Genet       Date:  2013-05-29       Impact factor: 8.929

Review 4.  BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.

Authors:  M Spaargaren; M F M de Rooij; A P Kater; E Eldering
Journal:  Oncogene       Date:  2014-06-23       Impact factor: 9.867

5.  PKCbeta modulates antigen receptor signaling via regulation of Btk membrane localization.

Authors:  S W Kang; M I Wahl; J Chu; J Kitaura; Y Kawakami; R M Kato; R Tabuchi; A Tarakhovsky; T Kawakami; C W Turck; O N Witte; D J Rawlings
Journal:  EMBO J       Date:  2001-10-15       Impact factor: 11.598

6.  Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer.

Authors:  Leila Kokabee; Xianhui Wang; Christopher J Sevinsky; Wei Lin Winnie Wang; Lindsay Cheu; Sridar V Chittur; Morteza Karimipoor; Martin Tenniswood; Douglas S Conklin
Journal:  Cancer Biol Ther       Date:  2015-09-18       Impact factor: 4.742

7.  Bruton's tyrosine kinase regulates immunoglobulin promoter activation in association with the transcription factor Bright.

Authors:  Jaya Rajaiya; Melissa Hatfield; Jamee C Nixon; David J Rawlings; Carol F Webb
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

Review 8.  B-lymphocyte tolerance and effector function in immunity and autoimmunity.

Authors:  Wasif N Khan; Jacqueline A Wright; Eden Kleiman; Justin C Boucher; Iris Castro; Emily S Clark
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

9.  TAPP1 and TAPP2 are targets of phosphatidylinositol 3-kinase signaling in B cells: sustained plasma membrane recruitment triggered by the B-cell antigen receptor.

Authors:  Aaron J Marshall; Allyson K Krahn; Kewei Ma; Vincent Duronio; Sen Hou
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

10.  Role of Ca2+ in the intracellular signaling pathway of anti-IgM-induced apoptosis in the human B-cell line, MBC-1, established from Burkitt lymphoma.

Authors:  Masamune Higashigawa; Yoshihiro Komada
Journal:  Int J Hematol       Date:  2002-07       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.